Table 2

Univariate and multivariate analyses of clinicopathological factors associated with DFS and OS

CharacteristicsNDFSOS
UnivariateMultivariateUnivariateMultivariate
P valueP valueP valueP value
HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)
Age (years)
 <63620.7470.89
 ≥63751.09 (0.65 to 1.84)0.96 (0.54 to 1.70)
Sex
 Male1130.5480.635
 Female241.24 (0.64 to 2.69)1.20 (0.59 to 2.75)
Differentiation
 Well or moderately1160.2090.223
 Poorly211.66 (0.77 to 4.31)1.71 (0.74 to 4.93)
T classification
 T1 or T2780.1650.361
 T3 or T4590.69 (0.42 to 1.16)0.77 (0.44 to 1.35)
N classification
 N0-1620.450.999
 N2-3751.21 (0.73 to 2.03)1.00 (0.57 to 1.75)
p16
 Positive59<0.001*<0.001*
 Negative780.24 (0.12 to 0.46)0.16 (0.06 to 0.37)
Definitive treatment
 Surgery530.7750.297
 CRT or RT840.92 (0.55 to 1.55)0.73 (0.40 to 1.31)
TC-PD-L1
 Positive810.08*0.0360.808
 Negative560.63 (0.37 to 1.06)0.54 (0.31 to 0.96)0.92 (0.48 to 1.76)
IC-PD-L1
 Positive830.008*0.036*<0.001*0.010*
 Negative540.50 (0.29 to 0.83)0.56 (0.33 to 0.96)0.36 (0.20 to 0.65)0.43 (0.22 to 0.82)
CD8
 High (≥18.6)690.024*0.1210.011*0.119
 Low (<18.6)680.54 (0.32 to 0.92)0.64 (0.37 to 1.12)0.47 (0.25 to 0.84)0.61 (0.31 to 1.13)
  • Significant differences were evaluated using a Cox proportional hazards model.

  • CRT, chemoradiotherapy; DFS, disease-free survival; IC-PD-L1, programmed death ligand 1 on immune cells; OS, overall survival; RT, radiotherapy; TC-PD-L1, programmed death ligand 1 on tumour cells.